Corvus Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Adams Street Partners, LLC updated its beneficial ownership in Corvus Pharmaceuticals, Inc. to 3.9% following a recent public offering by the issuer.
NASDAQ
SCHEDULE 13D/A: OrbiMed's Corvus Stake Dips Post-Offering
OrbiMed Advisors' beneficial ownership in Corvus Pharmaceuticals decreased to 10.3% following Corvus's recent public offering of 7.9 million shares.
NASDAQ
SCHEDULE 13D/A: OrbiMed Advisors Updates Corvus Pharmaceuticals Stake to 12.2% Following Share Count Adjustment
OrbiMed Advisors LLC and OrbiMed Capital GP V LLC have filed an Amendment No. 11 to their Schedule 13D, reporting a decrease in their beneficial ownership of Corvus Pharmaceuticals, Inc. common stock to 12.2% due to a change in the number of outstanding shares.
NASDAQ
SCHEDULE 13D/A: OrbiMed Advisors Increases Beneficial Ownership in Corvus Pharmaceuticals to 13.8% and Expands Warrant Exercise Blocker
OrbiMed Advisors and OrbiMed Capital GP V have filed an amendment to their Schedule 13D, disclosing an increased beneficial ownership of 13.8% in Corvus Pharmaceuticals, Inc. and an expanded warrant exercise limitation.